Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Axitinib vs Sunitinib in first-line metastatic renal cell carcinoma
NCT02853331Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02853331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853331.